TME Pharma

The publications contained in this archive section are provided for historical purposes only. The views expressed in the publications are those of their respective authors and do not reflect the views of TME Pharma. TME Pharma disavows any obligation to update or correct the information contained in these publications.

Zboralski D, Hoellenriegel J, Maasch C, Kruschinski A, Burger JA
Mode of Action of the SDF-1/CXCL12 Inhibiting Spiegelmer NOX-A12 and Its Impact On Chronic Lymphocytic Leukemia (CLL) Cell Motility and Chemosensitization.
Blood (ASH Annual Meeting Abstracts) 2012 120: Abstract 318
read ASH abstract on

Gobbi M, Caligaris-Cappio F, Montillo M, Vauléon S, Zöllner S, Dümmler T, Kruschinski A, Fliegert F
Phase IIa Study of the Anti-CXCL12/SDF-1 Spiegelmer NOX-A12 Alone and Combined with Bendamustine/Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL).
Blood (ASH Annual Meeting Abstracts) 2012 120: Abstract 4593logylibrary
read ASH abstract on

Riecke K, Zöllner S,Boyce M, Vauléon S, Swinkels DW, Dümmler T, Summo L, Laarakkers C, Schwoebel F, Fliegert F
Single and Repeated Dose First-in-Human Study with the Anti-Hepcidin Spiegelmer NOX-H94.
Blood (ASH Annual Meeting Abstracts) 2012 120: Abstract 2342
read ASH abstract on

van Eijk L, Swinkels DW, Aaron J,Schwoebel F, Fliegert F, Summo L, Vauleon S, Laarakkers C, Riecke K, Pikkers P
Randomized Double Blind Placebo Controlled PK/PD Study On the Effects of a Single Intravenous Dose of the Anti-Hepcidin Spiegelmer NOX-H94 On Serum Iron During Experimental Human Endotoxemia.
Blood (ASH Annual Meeting Abstracts) 2012 120: Abstract 3452
read ASH abstract on

Savai R, Pullamsetti SS, Kolbe J, Bieniek E, Voswinckel R, Fink L, Scheed A, Ritter C, Dahal BK, Vater A, Klussmann S, Ghofrani HA, Weissmann N, Klepetko W, Banat GA, Seeger W, Grimminger F, Schermuly RT.
Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension.
Am J Respir Crit Care Med. 2012, Vol. 186(9), 897-908.
view PubMed abstract on

Baeck C, Wehr A, Karlmark KR, Heymann F, Vucur M, Gassler N, Huss S, Klussmann S, Eulberg D, Luedde T, Trautwein C, Tacke F.
Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury.
GUT 2012, Vol. 61(3), 416-26.
view PubMed abstract on

Hoffmann S, Hoos J, Klussmann S, Vonhoff S.
RNA aptamers and spiegelmers: synthesis, purification, and post-synthetic PEG conjugation.
Curr. Protoc. Nucleic Acid Chem. 2011, Chapter 4: Unit 4.46, 1-30.
view PubMed abstract on

Turner JJ, Hoos JS, Vonhoff S, Klussmann S.
Methods for L-ribooligonucleotide sequence determination using LCMS.
Nucl. Acids Res. 2011, Vol. 39(21), e147.
read article

Darisipudi MN, Kulkarni OP, Sayyed SG, Ryu M, Migliorini A, Sagrinati C, Parente E, Vater A, Eulberg D, Klussmann S, Romagnani P, Anders HJ.
Dual Blockade of the Homeostatic Chemokine CXCL12 and the Proinflammatory Chemokine CCL2 Has Additive Protective Effects on Diabetic Kidney Disease.
Am J Pathol. 2011, Vol. 179(1), 116-24.
view PubMed abstract on

Sangiao-Alvarellos S, Helmling S, Vázquez MJ, Klussmann S, Cordido F.
Ghrelin neutralization during fasting-refeeding cycle impairs the recuperation of body weight and alters hepatic energy metabolism.
Mol. Cell. Endocrinol. 2011 Jan 15.
view PubMed abstract on

We use cookies

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (Google Analytics cookies). You can decide for yourself whether you want to accept the cookies. Please note that if you refuse cookies, you may no longer be able to use all of the site's functions.